Dehydrozingerone

Dehydrozingerone

SCHEMBL9104958

COC.COc1cc(C=CC(C)=O)ccc1O

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 3/20 0.97
CYP2D6 P10635 3/20 0.77
NFKB1 P19838 3/20 0.77
CYP1A2 P05177 2/20 0.77
ALOX5 P09917 2/20 0.77
HSD11B1 P28845 2/20 0.77
STAT3 P40763 2/20 0.77
NFKB2 Q00653 2/20 0.77
RELA Q04206 2/20 0.77
NFE2L2 Q16236 2/20 0.77
KDM4E B2RXH2 2/20 0.74
CA12 O43570 2/20 0.74
CA1 P00915 2/20 0.74
CA2 P00918 2/20 0.74
CA3 P07451 2/20 0.74
PKM P14618 2/20 0.74
CA4 P22748 2/20 0.74
CA6 P23280 2/20 0.74
CA5A P35218 2/20 0.74
SNCA P37840 2/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dehydrozingerone SCHEMBL30310276 0.98 APP (1.00) APPCYP2D6NFKB1CYP1A2ALOX5
Dehydrozingerone SCHEMBL498224 0.98 APP (1.00) APPCYP2D6NFKB1CYP1A2ALOX5
Dehydrozingerone SCHEMBL29691993 0.98 APP (1.00) APPCYP2D6NFKB1CYP1A2ALOX5
Dehydrozingerone SCHEMBL498223 0.98 APP (1.00) APPCYP2D6NFKB1CYP1A2ALOX5
Dehydrozingerone SCHEMBL27764046 0.90 APP (0.83) APPCYP2D6NFKB1CYP1A2ALOX5
SCHEMBL30668505 0.87 CYP2D6 (1.00) APPCYP2D6NFKB1CYP1A2ALOX5
SCHEMBL1493283 0.87 CYP2D6 (1.00) APPCYP2D6NFKB1CYP1A2ALOX5
SCHEMBL1493282 0.87 CYP2D6 (1.00) APPCYP2D6NFKB1CYP1A2ALOX5
SCHEMBL29478095 0.87 CYP2D6 (1.00) APPCYP2D6NFKB1CYP1A2ALOX5
SCHEMBL9907021 0.86 APP (0.78) APPCYP2D6NFKB1CYP1A2ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2649033-B1 COMPOSITIONS AND METHODS FOR STABILIZING INGREDIENTS USING 2,4-PENTANEDIONE COMPOUNDS SYTHEON LTD (US) 2018-10-17 EP disclosed
US-8617528-B2 Compositions and methods for stabilizing ingredients using 2,4-pentanedione compounds SYTHEON LTD. (US) 2013-12-31 US disclosed
US-20120141395-A1 COMPOSITIONS AND METHODS FOR STABILIZING INGREDIENTS USING 2,4-PENTANEDIONE COMPOUNDS SYTHEON LIMITED (US) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120141395-A1 COMPOSITIONS AND METHODS FOR STABILIZING INGREDIENTS USING 2,4-PENTANEDIONE COMPOUNDS HPD, GPX4, RBP4 APP 448/4885CYP2D6 1065/4885NFKB1 2839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.